Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials

Coleman, R.E. orcid.org/0000-0002-4275-1043, Lipton, A., Costa, L. et al. (9 more authors) (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2 (2). pp. 70-76. ISSN 2212-1366

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Breast cancer; Non-small cell lung cancer; N-telopeptide of type I collagen; Prostate cancer; Survival; Zoledronic acid
Dates:
  • Published: June 2013
  • Published (online): 9 February 2013
  • Accepted: 14 January 2013
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 08 Aug 2016 10:58
Last Modified: 08 Aug 2016 10:58
Published Version: http://dx.doi.org/10.1016/j.jbo.2013.01.002
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jbo.2013.01.002
Related URLs:

Share / Export

Statistics